gbio-logo .png
Generation Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 16:05 ET | Generation Bio Co.
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases,...
gbio-logo .png
Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms
November 29, 2023 06:59 ET | Generation Bio Co.
Company to invest in highly selective cell-targeted lipid nanoparticle (ctLNP) delivery platform to develop wholly-owned programs for extrahepatic cell typesDevelopment of immune-quiet DNA (iqDNA)...
gbio-logo .png
Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results
November 09, 2023 16:15 ET | Generation Bio Co.
-  Immune-quiet DNA evades innate immune sensors in both mice and non-human primates addressing a central challenge for non-viral DNA therapeutics -  Proprietary cell-targeted LNP delivery system...
Figure 1
Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform
October 26, 2023 06:59 ET | Generation Bio Co.
70% of circulating and splenic T cells positive for mRNA expression in humanized mice with less than 8% delivery to off-target immune cells Stealth properties of cell-targeted lipid nanoparticle...
IL-6
Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA
October 18, 2023 06:59 ET | Generation Bio Co.
– Immune-quiet DNA (iqDNA) is a novel variant of closed-ended DNA (ceDNA) that evades host innate immune detection in both mice and non-human primates (NHPs) with a systemic cytokine profile and...
gbio-logo .png
Generation Bio to Present at the Jefferies Cell & Genetic Medicine Summit
September 19, 2023 07:30 ET | Generation Bio Co.
CAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases,...
gbio-logo .png
Generation Bio to Present at the Canaccord Genuity 43rd Annual Growth Conference 
August 03, 2023 07:30 ET | Generation Bio Co.
CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases,...
gbio-logo .png
Generation Bio Reports Second Quarter 2023 Financial Results
August 02, 2023 16:15 ET | Generation Bio Co.
CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) --  Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases,...
gbio-logo .png
Generation Bio to Present at the 2023 Jefferies Healthcare Conference
May 31, 2023 07:30 ET | Generation Bio Co.
CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases,...
gbio-logo .png
Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results
May 10, 2023 16:15 ET | Generation Bio Co.
Company entered into strategic collaboration with Moderna to use Generation Bio’s proprietary non-viral genetic medicine delivery system for two liver disease programs and to co-develop novel...